![A line drawing of a laptop and a cup of coffee](/sites/default/files/2020-12/hero-laptop.png)
This resource describes how state health departments and other public health organizations can partner with people with HIV and/or who use(d) drugs in programmatic and policy making processes and evaluation.
This resource describes how state health departments and other public health organizations can partner with people with HIV and/or who use(d) drugs in programmatic and policy making processes and evaluation.
Language is foundational to how we understand and interact with ourselves and others. Unclear language can lead to confusion and inefficiencies, while stigmatizing and prejudicial language leads to harmful practices and dehumanizes people.
Articles in this supplement focus on the global opioid crisis, including coverage of harm reduction approaches, health justice promotion, and lessons learned.
The COVID-19 pandemic resulted in federal policy changes related to telehealth use that allowed states to maximize access to medications for opioid use disorder (MOUD) through telehealth.
Individuals who have HIV who also use drugs experience increased age-matched morbidity and mortality in comparison with those with HIV who do not use drugs.
This document describes the critical role that peers have in developing and delivering care for people with HIV and OUD and how a state’s Medicaid program can serve as an essential fiscal resource in supporting peer services.
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.
This article describes how the HIV testing window period is a challenge related to prescribing PrEP for people who inject drugs, and discusses current approaches and how data are needed to help guide best practices.